文献速递妇科生殖医学

Ⅰ期胎盘部位滋养细胞肿瘤降阶梯治疗与保留生育功能的个体患者数据系统评价

De-escalation strategies and fertility preservation in Stage I placental site trophoblastic tumor: an individual patient data systematic review and institutional series.
PubMed 文献 · Gynecol Oncol · 2026-11-04

本研究整合机构队列(2015-2021年,36例)与系统文献复习(1990-2021年,193例),共229例Ⅰ期胎盘部位滋养细胞肿瘤患者。结果显示ISAP≥48个月为最佳截断值,可独立预测无进展生存和总生存;低危患者单纯手术结局良好,保留生育功能手术可行。

要点

  • ISAP≥48个月是Ⅰ期PSTT的稳健预后因素,独立预测无进展生存和总生存。
  • 低危患者未化疗者无进展或死亡事件(0/85),单纯手术结局优秀。
  • 严格选择的低危患者可行保留生育功能手术,补救性子宫切除有效。

核心结论

  • ISAP≥48个月是Ⅰ期PSTT稳健的预后决定因素。
  • 低危患者单纯手术结局优秀,化疗可否安全省略待前瞻性试验确认。
  • 保留生育功能手术对严格选择的低危候选者可行,补救性子宫切除提供有效控制。

研究设计与样本

  • 机构队列(2015-2021年,N=36)与系统文献复习(1990-2021年,N=193)整合,共229例。
  • 缺失数据采用多重插补处理。
  • 采用AIC/BIC确定最佳ISAP截断值,多因素Cox回归评估预后因素。

主要发现

  • 229例中50例(21.8%)接受保留生育功能手术。
  • ISAP≥48个月为最佳截断值,分层为174例低危(ISAP<48个月)和31例高危患者。
  • ISAP≥48个月独立预测无进展生存(HR 14.92,95%CI 3.68-60.38;P<0.001)和总生存(HR 20.90,95%CI 2.22-196.73;P=0.008)。
  • 病理风险因素无预后意义。
  • 低危患者未化疗者无进展或死亡事件(0/85)。

关键数值与推荐

  • ISAP≥48个月为最佳截断值,分层低危(<48个月)和高危(≥48个月)。
  • 低危患者未化疗者无进展或死亡事件(0/85)。
  • 保留生育功能手术患者中4例(8.0%)需补救性子宫切除。

临床怎么用

  • ISAP≥48个月可用于Ⅰ期PSTT风险分层。
  • 低危患者可考虑单纯手术,省略化疗需前瞻性试验确认。
  • 严格选择的低危候选者可考虑保留生育功能手术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study evaluates the statistical robustness of the ISAP cutoff proposed by the 2025 guidelines, re-assesses traditional pathological prognostic factors, and identifies candidates for therapeutic de-escalation regarding chemotherapy omission and fertility-sparing surgery (FSS). METHODS: We harmonized an institutional cohort (2015-2021, N = 36) with a systematic literature review (1990-2021, N = 193). Missing data were handled via multiple imputation. The optimal ISAP cutoff was determined using AIC/BIC; prognostic factors were evaluated via multivariate Cox regression. RESULTS: Among 229 patients (50 [21.8%] undergoing FSS), ISAP ≥48 months emerged as the optimal cutoff, stratifying 174 low-risk (ISAP <48 months) and 31 high-risk patients. ISAP ≥48 months independently predicted progression-free survival (HR 14.92, 95% CI 3.68-60.38; P < 0.001) and overall survival (HR 20.90, 95% CI 2.22-196.73; P = 0.008). Pathological risk factors showed no prognostic significance. Among low-risk patients managed without chemotherapy, no progression or mortality events occurred (0/85). Four (8.0%) FSS patients required salvage hysterectomy; all achieved 100% survival and none required completion hysterectomy after childbearing. CONCLUSIONS: ISAP ≥48 months is a robust prognostic determinant in Stage I PSTT. Surgery alone achieved excellent outcomes in low-risk patients; prospective trials should confirm whether chemotherapy can be safely omitted. FSS is viable for strictly selected low-risk candidates, with salvage hysterectomy providing effective control and subsequent term pregnancies documented.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chen J, Zhu G, Sun Y, et al. De-escalation strategies and fertility preservation in Stage I placental site trophoblastic tumor: an individual patient data systematic review and institutional series. Gynecol Oncol. 2026. PMID: 42981794. doi:10.1016/j.ygyno.2026.10.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。